Pasar al contenido principal

ESTUDIO LONGITUDINAL DEL EFECTO DEL CONSUMO DE ALCOHOL Y DROGAS EN LA PERMEABILIDAD INTESTINAL, INFLAMACION SISTEMICA, ESTRES OXIDATIVO Y LA SALUD CARDIOVASCULAR

PI17/00174

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hepatitis C infection substantially reduces survival of alcohol-dependent patients

  • Muga, Roberto|||0000-0001-6301-431X
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Jarrín, Inma|||0000-0002-7485-2252
  • Fuster, Daniel|||0000-0003-1262-5860
  • Bolao, Ferran|||0000-0002-9104-6615
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Muñoz, Alvaro|||0000-0002-4037-0490
Heavy alcohol use is associated with life-threatening complications including progressive liver disease. We aimed to analyze the impact of hepatitis C virus (HCV) infection on survival and liver-related death in alcohol-dependent patients. This is a longitudinal study in patients seeking treatment of alcohol abuse between 2000 and 2010. Information on alcohol use characteristics, alcoholic liver disease, and HCV infection were obtained at entry. Cumulated mortality and causes of death were ascertained through clinical records and death registry. A total of 819 patients (81.6% men) underwent ethanol detoxification; age was 44 (inter-quartile range [IQR] 38-51) years; the duration of heavy alcohol use was 14 (IQR 6-24) years; and the alcohol consumption was 190 (IQR 120-250) g/day. The prevalence of HCV infection was 15.8%. There were 129 (16.9%) deaths during 5,117 persons-year (p-y) of follow-up (median follow-up 6.4 [IQR 4.3-9.2] years); 31 (24.6%) deaths were observed among the HCV-positive patients, and 98 (15.4%) deaths were observed among the HCV-negative patients. The mortality rate was significantly (P =0.03) higher among the HCV-positive patients (3.84×100 p-y; 95% confidence interval [CI]: 2.70, 5.46) than among the HCV-negative patients (2.27×100 p-y; 95% CI: 1.86, 2.77). Survival times for the HCV infected patients were 34% shorter (time ratio relative to HCV negative: 0.66; 95% CI: 0.51, 0.86). The main causes of death in the HCV-positive and -negative patients were liver-related mortality (48.4%) and neoplasia (22.4%), respectively. The liver-related mortality was significantly higher among the HCV-positive patients (adjusted sub-distribution hazard ratio [asHR] 3.65; 95% CI: 1.72, 7.78; P =0.001). HCV infection compromises the survival of patients with alcohol abuse/dependence. The new direct antiviral agents for the treatment of HCV infection may result in better clinical outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-Term Outcomes of Patients With Cocaine Use Disorder, A 18-years Addiction Cohort Study

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Zuluaga Cruz, Andrea Paola|||0000-0002-3003-4856
  • Fuster, Daniel|||0000-0003-1262-5860
  • Papaseit, Esther|||0000-0003-2620-4274
  • Galan, Sara
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Muga, Roberto|||0000-0001-6301-431X
Objective: Cocaine Use Disorder (CUD) has been associated with multiple complications and premature death. The purpose of the present study was to analyze the relationship between baseline medical comorbidity and long-term medical outcomes (i.e., hospitalization, death) in a cohort of patients primarily admitted for detoxification. In addition, we aimed to analyze cause-specific mortality. Methods: longitudinal study in CUD patients admitted for detoxification between 2001 and 2018. Substance use characteristics, laboratory parameters and medical comorbidity by VACS Index were assessed at admission. Follow-up and health-related outcomes were ascertained through visits and e-health records. Kaplan-Meier and Cox regression models were used to analyze survival and predictors of hospitalization and death. Results: 175 patients (77.7% men) were included. Age at admission was 35 years [IQR: 30-41 years], 59.4% of the patients being intranasal users, 33.5% injectors, and 7.1% smokers. Almost 23% of patients had concomitant alcohol use disorder, 39% were cannabis users and 9% opiate users. The median VACS Index score on admission was 10 points [IQR: 0-22]. After 12 years [IQR: 8.6-15 years] of follow-up there were 1,292 (80.7%) ED admissions and 308 (19.3%) hospitalizations. The incidence rate of ED admission and hospitalization was 18.6 × 100 p-y (95% CI: 15.8-21.8 × 100 p-y). Mortality rate was 1.4 × 100 p-y (95% CI: 0.9-2.0 × 100 p-y) and, baseline comorbidity predicted hospitalization and mortality: those with VACS Index.
Dipòsit Digital de Documents de la UAB
Publicación

Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program, A longitudinal study

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Rivas, Inmaculada|||0000-0003-2633-5530
  • Faure, Eva|||0000-0002-5056-0888
  • Espinach, Néstor|||0000-0002-5726-5435
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Majó, Xavier|||0000-0003-4338-6014
  • Colom Farran, J.|||0000-0001-6861-7865
  • Muga, Roberto|||0000-0001-6301-431X
Direct-acting antivirals (DAAs) are recommended for the treatment of hepatitis C virus (HCV) infection in patients treated with methadone or buprenorphine. To assess HCV treatment rates in an Opioid Treatment Program (OTP). This longitudinal study included 501 patients (81.4% men, median age: 45 years; interquartile range: 39-50 years) enrolled in an OTP between October 2015 and September 2017. Patients were followed until September 2019. Data on socio-demographics, substance use, HCV infection, human immunodeficiency virus (HIV) infection and laboratory parameters were collected at entry. We analyzed medical records to evaluate HCV treatment. Kaplan-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment predictors. Prevalence of HCV and HIV infection was 70% and 34%, respectively. Among anti-HCV-positive (n = 336) patients, 47.2%, 41.3%, and 31.9% used alcohol, cannabis, and cocaine, respectively. HCV-RNA tests were positive in 233 (69.3%) patients. Twentyeight patients (8.3%) cleared the infection, and 59/308 (19.1%) had received interferon-based treatment regimens before 2015. Among 249 patients eligible, 111 (44.6%) received DAAs. Treatment rates significantly increased over time from 7.8/100 person-years (p-y) (95%CI: 5.0-12.3) in 2015 to 18.9/100 p-y (95%CI: 11.7-30.3) in 2019. In a multivariate analysis, patients with HIV co-infection were twice as likely to receive DAAs (HR = 1.94, 95%CI: 1.21-3.12) than patients with HCV mono-infection. Current drug use was an independent risk factor for not receiving treatment against infection (HR = 0.48, 95%CI: 0.29-0.80). HCV treatment is evolving in patients with HCV-HIV co-infection. Ongoing drug use while in an OTP might negatively impact the readiness to treat infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use

  • Fuster, Daniel|||0000-0003-1262-5860
  • García Calvo, Xavier|||0000-0001-8165-8717
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Bolao, Ferran|||0000-0002-9104-6615
  • Muga, Roberto|||0000-0001-6301-431X
Hepatitis C virus (HCV) infection and unhealthy alcohol use are major drivers of the burden of liver disease worldwide and commonly co-occur. Assessment of underlying liver damage is a cornerstone of the clinical care of patients with chronic HCV infection and/or unhealthy alcohol use because many of them are diagnosed at advanced stages of disease. Early diagnosis of liver disease before decompensated liver cirrhosis becomes established is essential for treatment with direct acting antivirals and/or abstinence from alcohol consumption, which are the main therapeutic approaches for clinical management. In this review, we discuss current knowledge around the use of non-invasive methods to assess liver disease, such as abdominal ultrasound, controlled attenuation parameter, transient elastography, magnetic resonance imaging, and indices based on serum markers of liver injury.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients

  • Fuster, Daniel|||0000-0003-1262-5860
  • Nunes, David
  • Cheng, Debbie
  • Saitz, Richard
  • Samet, Jeffrey H.|||0000-0002-0897-3400
Background: The impact of Hepatitis C virus (HCV) RNA levels on the evolution of chronic HCV infection-related liver damage is controversial. Heavy alcohol use is believed to have a deleterious impact on the course of HCV disease, but current knowledge about the possible effect of alcohol use on HCV RNA levels in HIV/HCV coinfected patients is limited. Methods: We examined 107 HIV/HCV-infected individuals with current or past unhealthy alcohol use to assess the association between alcohol consumption (any drinking vs. abstinent) and HCV RNA levels. Results: Participants were 75% male, with a mean age of 43 years, and 63% were on antiretroviral therapy. Mean (SD) log HIV RNA was 3.1 (1.4) and mean (SD) log HCV RNA was 6.1 (0.8). Past-month alcohol use was present in 38% of participants. In a multivariable linear regression analysis we found no significant differences in mean log HCV RNA levels between those reporting alcohol use and those who were abstinent [β (95%CI): -0.04 (-0.34, 0.26), p = 0.79)]. There was no significant association between any heavy drinking day and HCV RNA level (0.07, 95% CI: (-0.24, 0.38), p = 0.66). Conclusions: We did not detect significant associations between alcohol use and HCV RNA levels among HIV/HCV coinfected patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence and associations of metabolic syndrome in patients with alcohol use disorder

  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Bolao, Ferran|||0000-0002-9104-6615
  • Cachón-Suárez, Isabel
  • Garcia-Martín, Carme
  • Short, Antoni
  • Bataller, Ramon|||0000-0002-1119-7799
  • Muga, Roberto|||0000-0001-6301-431X
Excessive alcohol consumption has been associated with different components of the metabolic syndrome (MetS) such as arterial hypertension, dyslipidemia, type 2 diabetes or obesity. We aimed to analyze the prevalence and associations of MetS in patients with Alcohol Use Disorder (AUD). Cross-sectional study in heavy drinkers admitted for the treatment of AUD between 2013 and 2017. Medical comorbidity, anthropometric data, alcohol use and biological parameters were obtained. MetS was established according to the harmonized definition. A total of 728 patients (22% women) were included; median age was 47 years (IQR: 40-53.5), median alcohol consumption was 160 g/day (IQR: 115-240) and prevalence of MetS was 13.9%. The multivariate analysis showed a significant dose-response effect of estimated glomerular filtration (eGFR) and MetS: relative to patients with eGFR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Markers of monocyte activation, inflammation, and microbial translocation are associated with liver fibrosis in alcohol use disorder

  • Fuster, Daniel|||0000-0003-1262-5860
  • García Calvo, Xavier|||0000-0001-8165-8717
  • Farré, Oriol
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Bolao, Ferran|||0000-0002-9104-6615
  • Leis, Alba|||0000-0003-3928-7849
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Rivas, Inmaculada|||0000-0003-2633-5530
  • Muga, Roberto|||0000-0001-6301-431X
Background: The association between markers of inflammation (interleukin (IL)-6 and IL-10), monocyte activation (sCD163 and sCD14), and microbial translocation (lipopolysaccharide (LPS) and LPS binding protein) and liver fibrosis in patients with alcohol use disorder (AUD) and no overt liver disease is not well established. Methods: We studied patients admitted for treatment of AUD at two hospitals in Barcelona. Advanced liver fibrosis (ALF) was defined as FIB-4.